Use of a Modified α-N-Acetylgalactosaminidase in the Development of Enzyme Replacement Therapy for Fabry Disease
Open Access
- 22 October 2009
- journal article
- research article
- Published by Elsevier BV in American Journal of Human Genetics
- Vol. 85 (5), 569-580
- https://doi.org/10.1016/j.ajhg.2009.09.016
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Reduced α-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry diseaseMolecular Genetics and Metabolism, 2008
- Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3Molecular Genetics and Metabolism, 2008
- Establishment of immortalized Schwann cells from Fabry mice and their low uptake of recombinant α-galactosidaseJournal of Human Genetics, 2007
- High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*American Journal of Human Genetics, 2006
- Corrective effect on Fabry mice of yeast recombinant human α-galactosidase with N-linked sugar chains suitable for lysosomal deliveryJournal of Human Genetics, 2006
- Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and betaKidney International, 2004
- The Molecular Defect Leading to Fabry Disease: Structure of Human α-GalactosidaseJournal of Molecular Biology, 2004
- Sphingolipid Activator ProteinsPublished by Wiley ,2002
- Rapid Production of Retroviruses for Efficient Gene Delivery to Mammalian Cells Using 293T Cell–Based SystemsCurrent Protocols in Immunology, 1999
- Galactose Stabilizes Various Missense Mutants of α-Galactosidase in Fabry DiseaseBiochemical and Biophysical Research Communications, 1995